-
1.发明授权Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules 有权集落刺激因子1受体（CSF1R）细胞外结构域融合分子公开(公告)号：US08080246B2
公开(公告)日：2011-12-20
申请号：US12626598
申请日：2009-11-25
Applicant: Haishan Lin , Li Long
Inventor： Haishan Lin , Li Long
CPC classification number: C07K14/7153 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).
Abstract translation: 本发明涉及具有改善的治疗性质的特异性CSF1R ECD融合分子。 本发明还涉及包含或编码这种分子的多肽和多核苷酸序列，载体，宿主细胞和组合物。 本发明还涉及制备和使用CSF1R ECD融合分子的方法。 本发明还涉及使用CSF1R ECD融合分子的治疗方法。 例如，本发明的某些CSF1R ECD可用于治疗类风湿性关节炎（RA）或多发性硬化症（MS）。
-
2.发明申请公开(公告)号：US20100136007A1
公开(公告)日：2010-06-03
申请号：US12626598
申请日：2009-11-25
Applicant: Haishan LIN , Li Long
Inventor： Haishan LIN , Li Long
CPC classification number: C07K14/7153 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).
Abstract translation: 本发明涉及具有改善的治疗性质的特异性CSF1R ECD融合分子。 本发明还涉及包含或编码这种分子的多肽和多核苷酸序列，载体，宿主细胞和组合物。 本发明还涉及制备和使用CSF1R ECD融合分子的方法。 本发明还涉及使用CSF1R ECD融合分子的治疗方法。 例如，本发明的某些CSF1R ECD可用于治疗类风湿性关节炎（RA）或多发性硬化症（MS）。
-
3.发明授权Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules 有权使用CSF1R细胞外结构域融合分子治疗溶骨性疾病和癌症公开(公告)号：US08183207B2
公开(公告)日：2012-05-22
申请号：US12626583
申请日：2009-11-25
Applicant: Haishan Lin , Li Long
Inventor： Haishan Lin , Li Long
CPC classification number: C07K14/70567 , A61K38/1793 , A61K47/60 , A61K47/643 , C07K2319/30
Abstract: Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.
Abstract translation: 提供了使用集落刺激因子受体（CSF1R）胞外域（ECD）融合分子治疗溶骨性骨丢失，癌转移，癌转移诱导的溶骨性骨丢失和肿瘤生长的方法。 还提供了CSF1R ECD融合分子，编码CSF1R ECD融合分子的多核苷酸，以及制备CSF1R ECD融合分子的方法。
-
4.发明申请TREATMENT OF OSTEOLYTIC DISORDERS AND CANCER USING CSF1R EXTRACELLULAR DOMAIN FUSION MOLECULES 有权使用CSF1R细胞域融合分子治疗骨质疏松症和癌症公开(公告)号：US20100136006A1
公开(公告)日：2010-06-03
申请号：US12626583
申请日：2009-11-25
Applicant: Haishan LIN , Li Long
Inventor： Haishan LIN , Li Long
IPC: A61K39/395 , A61K38/16 , A61P35/00 , A61P37/04
CPC classification number: C07K14/70567 , A61K38/1793 , A61K47/60 , A61K47/643 , C07K2319/30
Abstract: Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules to treat treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.
Abstract translation: 提供了使用集落刺激因子受体（CSF1R）细胞外结构域（ECD）融合分子治疗溶骨性骨丢失，癌症转移，癌转移诱导的溶骨性骨丢失和肿瘤生长的方法。 还提供了CSF1R ECD融合分子，编码CSF1R ECD融合分子的多核苷酸，以及制备CSF1R ECD融合分子的方法。
-
公开(公告)号：US08637032B2
公开(公告)日：2014-01-28
申请号：US13612070
申请日：2012-09-12
Applicant: Li Long , Asha Yabannavar , Isabel Zaror , Sang Hoon Lee , Deborah Hurst
Inventor： Li Long , Mohammad Luqman , Asha Yabannavar , Isabel Zaror , Sang Hoon Lee , Deborah Hurst
IPC: A61K39/395 , C07K16/28
CPC classification number: C07K16/2878 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K47/6849 , A61K2039/505 , A61K2039/507 , A61N5/10 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
Abstract translation: 提供了用于治疗通过CD40表达细胞刺激CD40信号传导介导的疾病的组合物和方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有利地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
Patent Agency Ranking
公开(公告)号：US20130136740A1
公开(公告)日：2013-05-30
申请号：US13675255
申请日：2012-11-13
Applicant: Thomas Harding , Servando Palencia , Li Long , Kevin Hestir
Inventor： Thomas Harding , Servando Palencia , Li Long , Kevin Hestir
IPC: A61K38/17 , A61K45/00 , A61K39/395
CPC classification number: A61K38/179 , A61K39/395 , A61K45/00 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6813 , C12Q1/686 , G01N33/5005 , A61K2300/00
Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
Abstract translation: 提供了治疗包含FGFR1基因扩增的癌症的方法。 在一些实施方案中，所述方法包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子。 在一些实施方案中，所述方法包括与至少一种另外的治疗剂组合施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子。
-
7.发明申请Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia 审中-公开使用拮抗剂抗CD40抗体治疗慢性淋巴细胞性白血病公开(公告)号：US20070110754A1
公开(公告)日：2007-05-17
申请号：US10577642
申请日：2004-11-04
Applicant: Li Long , Mohammad Luqman , Asha Yabannavar , Isabet Zaror , Sharon Aukerman
Inventor： Li Long , Mohammad Luqman , Asha Yabannavar , Isabet Zaror , Sharon Aukerman
IPC: A61K39/395 , C07K16/30
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
Abstract: Methods of therapy for treating a subject for chronic lymphocytic leukemia are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CN40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing chronic lymphocytic leukemia cells.
Abstract translation: 提供了治疗慢性淋巴细胞性白血病受试者的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CN40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制人CD40表达慢性淋巴细胞白血病细胞的增殖和/或分化。
-
公开(公告)号：US07392513B2
公开(公告)日：2008-06-24
申请号：US10804735
申请日：2004-03-19
Applicant: Li Long , Bo Huang , Jinquan Dai
Inventor： Li Long , Bo Huang , Jinquan Dai
CPC classification number: G06F8/443
Abstract: Methods and apparatus for merging critical sections are disclosed. An example disclosed system estimates the cost of merging a first critical section and a second critical section using a dataflow analysis on the first and second critical sections. In the example system, the first critical section and the second critical section are merged based on a least expensive cost of merging critical sections.
Abstract translation: 公开了合并关键部分的方法和装置。 公开的一个示例系统使用第一和第二关键部分上的数据流分析来估计合并第一关键部分和第二关键部分的成本。 在示例系统中，第一关键部分和第二关键部分基于合并关键部分的最低成本来合并。
-
9.发明申请公开(公告)号：US20130011405A1
公开(公告)日：2013-01-10
申请号：US13612070
申请日：2012-09-12
Applicant: Li Long , Mohammad Luqman , Asha Yabannavar , Isabel Zaror , Bao-Lu Chen , Xiaofeng Lu , Sang Hoon Lee , Deborah Hurst , Sharon Lea Aukerman , Daniel E. Lopes de Menezes
Inventor： Li Long , Mohammad Luqman , Asha Yabannavar , Isabel Zaror , Bao-Lu Chen , Xiaofeng Lu , Sang Hoon Lee , Deborah Hurst , Sharon Lea Aukerman , Daniel E. Lopes de Menezes
IPC: A61K39/395 , A61P29/00 , A61P19/04 , A61P35/00 , A61P19/02 , A61P19/08 , A61P37/06 , A61P25/00 , A61P1/16 , A61P1/00 , A61P7/06 , A61P31/14 , A61P17/06 , A61P21/04 , A61P5/14 , A61P37/00 , A61P7/02 , A61P9/00 , A61P3/10 , A61P37/08 , A61P11/06 , A61P25/28 , C12N5/0781 , A61K39/44
CPC classification number: C07K16/2878 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K47/6849 , A61K2039/505 , A61K2039/507 , A61N5/10 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
Abstract translation: 提供了用于治疗通过CD40表达细胞刺激CD40信号传导介导的疾病的组合物和方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有利地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
公开(公告)号：US20070098718A1
公开(公告)日：2007-05-03
申请号：US10578401
申请日：2004-11-04
Applicant: Li Long , Mohammad Luqman , Asha Yabannavar , Isabel Zaror
Inventor： Li Long , Mohammad Luqman , Asha Yabannavar , Isabel Zaror
IPC: A61K39/395 , C07K16/28
CPC classification number: C07K16/2878 , A61K2039/507 , C07K16/2887 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Methods of treating a human subject for a cancer characterized by neoplastic B cell growth are provided. The methods comprise administering combination antibody therapy to the subject, where an effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof in combination with an anti-CD20 antibody or antigenbinding fragment thereof is administered to the subject. The invention further comprises pharmaceutical compositions with combinations of these antibodies in a pharmaceutically acceptable carrier.
Abstract translation: 提供了治疗人受试者以肿瘤B细胞生长为特征的癌症的方法。 所述方法包括向受试者施用组合抗体治疗，其中将有效量的抗CD40抗体或其抗原结合片段与抗CD20抗体或其抗原结合片段组合施用于受试者。 本发明进一步包括在药学上可接受的载体中具有这些抗体的组合的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.034 seconds)
